Immutep Limited
Status: Publicly traded
Direct answer
Immutep Limited is publicly traded on NASDAQ under the ticker IMMP.
Immutep Limited, a biotechnology company, engages in developing novel Lymphocyte Activation Gene-3 related immunotherapies for cancer and autoimmune diseases in Australia. Its lead product candidate is the eftilagimod alfa (efti or IMP321), a soluble LAG-3lg fusion based on LAG-3 immune control mechanism for the treatment of different types of cancers. The company's product pipeline also includes TACTI-004, which is...
Can you invest in Immutep Limited?
Yes. Immutep Limited is publicly traded on NASDAQ under the ticker IMMP.
View deeper analysis
View detailed research on MarketSnap, including financials, valuation tools, and analyst context.
Open research for Immutep Limited
Detailed equity research is provided by MarketSnap.